Pfizer COVID-19 vaccine safe, effective on adolescents in trial, companies say
CHICAGO (Reuters) - Pfizer Inc and BioNTech SE said on Wednesday their COVID-19 vaccine was safe and effective and produced robust antibody responses in 12- to 15-year olds, paving the way for them to seek U.S. emergency use authorization in weeks. Read full story
Comments
Post a Comment